Nolpitantium besilate
Alternative Names: SR 140333Latest Information Update: 17 Jan 2008
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Class Analgesics; Anti-inflammatories; Antiasthmatics; Antihypotensives; Antimigraines; Piperidines; Quinuclidines; Small molecules
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Inflammation; Migraine; Nausea and vomiting; Pain; Ulcerative colitis
Most Recent Events
- 01 Apr 2005 No development reported - Phase-II for Asthma in France (unspecified route)
- 01 Apr 2005 No development reported - Phase-II for Inflammation in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis